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Age-related macular degeneration (AMD) is a common disorder that causes irreversible loss of central vision. Increased intake of foods containing zeax-
anthin may be effective in preventing AMD because the macula accumulates zeaxanthin and lutein, oxygenated carotenoids with antioxidant and blue light-
absorbing properties. Lycium barbarum L. is a small red berry known as Fructus lycii and wolfberry in the West, and Kei Tze and Gou Qi Zi in Asia.
Wolfberry is rich in zeaxanthin dipalmitate, and is valued in Chinese culture for being good for vision. The aim of this study, which was a single-blinded,
placebo-controlled, human intervention trial of parallel design, was to provide data on how fasting plasma zeaxanthin concentration changes as a result of
dietary supplementation with whole wolfberries. Fasting blood was collected from healthy, consenting subjects; fourteen subjects took 15 g/d wolfberry
(estimated to contain almost 3 mg zeaxanthin) for 28 d. Repeat fasting blood was collected on day 29. Age- and sex-matched controls (n 13) took no wolf-
berry. Responses in the two groups were compared using the Mann–Whitney test. After supplementation, plasma zeaxanthin increased 2·5-fold: mean
values on day 1 and 29 were 0·038 (SEM 0·003) and 0·096 (SEM 0·009) mmol/l (P,0·01), respectively, for the supplementation group; and 0·038 (SEM
0·003) and 0·043 (SEM 0·003) mmol/l (P.0·05), respectively, for the control group. This human supplementation trial shows that zeaxanthin in whole wolf-
berries is bioavailable and that intake of a modest daily amount markedly increases fasting plasma zeaxanthin levels. These new data will support further
study of dietary strategies to maintain macular pigment density.
Macular pigment: AMD: Zeaxanthin: Lutein: Fructus lycii: Kei Tze: Wolfberry: Antioxidant: Oxidative stress
Zeaxanthin is an oxygenated carotenoid (xanthophyll), and a
structural isomer of lutein (Edge et al. 1997; Moeller et al.
2000; Krinsky et al. 2003). Both zeaxanthin and lutein are con-
centrated in the fovea, or ‘yellow spot’, of the eye, and constitute
the macular pigment (Landrum & Bone, 2001). In humans, zeax-
anthin is located primarily in the central area of the macula, and
lutein is found more peripherally (Landrum et al. 1999; Bone et al.
2000). Thinning of the macular pigment is a common accompani-
ment to ageing, and is associated with irretrievable loss of central
vision, a condition known as age-related macular degeneration
(AMD; Beatty et al. 1999; Landrum & Bone, 2001; Hyman &
Neborsky, 2002). Currently there is no effective treatment for
AMD, which is the leading cause of blindness in those aged
.65 years (Stokkermans, 2000; Landrum & Bone, 2001).
The underlying causes of AMD are poorly understood, but it is
believed that oxidative damage to the lipid-rich retina owing to
loss of the protective macular pigment is a key factor (Beatty
et al. 2000; Landrum & Bone, 2001). The antioxidant properties
of lutein and zeaxanthin, along with their ability to absorb blue
light, are believed to protect the retina from photo-oxidative
damage, reduce light scatter within the eye, and thus maintain
visual acuity (Hammond et al. 2001; Landrum & Bone, 2001;
Benzie, 2003; Krinsky et al. 2003; Mozaffarieh et al. 2003).
Therefore, enhancement of macular pigment by increased dietary
intake of carotenoids is a suggested strategy to delay or prevent
AMD and enhance visual function (Hammond et al. 1997; Land-
rum et al. 1997; Moeller et al. 2000; Stokkermans, 2000). In this
regard, lutein has been the focus of several supplementation
studies (Landrum et al. 1997; Olmedilla et al. 2001; Bartlett &
Eperjesi, 2003; Bone et al. 2003). However, the potential benefit
of increased intake of zeaxanthin may be greater than that of
lutein, owing to the more centrally located foveal accumulation
of zeaxanthin.
The small red berry known variously as Fructus lycii, wolf-
berry, Kei Tze and Gou Qi Zi is the dried, ripe fruit of the
plant Lycium barbarum L. Wolfberry is rich in zeaxanthin,
around 90 % of which is in the form of the ester, zeaxanthin dipal-
mitate (Lam & But, 1999; Zhou et al. 1999; Weller & Breithaupt,
2003). Wolfberry is similar in texture and size to a raisin, and is
commonly consumed in China for its pleasant flavour and because
of its strong reputation in Chinese culture for being beneficial for
vision. The dried berries can be chewed and eaten without further
processing, but common practice is to add them to teas, soups and
stews. There are no published reports of which we are aware that
describe toxic effects or allergic reactions to ingestion of
wolfberry.
To date, published studies of plasma zeaxanthin response to
supplementation have used purified zeaxanthin or extracts of
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wolfberry (Leung et al. 2001; Bone et al. 2003; Breithaupt et al.
2004; Hartmann et al. 2004). Leung et al. (2001) showed that 6
weeks’ supplementation of monkeys (n 3) with a wolfberry
extract increased both their plasma and macular zeaxanthin con-
tent. Two recently published human trials focused on absorption
kinetics of zeaxanthin, one after repeated oral doses of purified,
free zeaxanthin (Hartmann et al. 2004), and the other on compar-
ing absorption kinetics after a single oral dose of zeaxanthin,
extracted from wolfberry, in its free or esterified form (Breithaupt
et al. 2004). The only food-based human supplementation study
we are aware of used egg yolk (Handleman et al. 1999). However,
ingestion of eggs has the disadvantage of increasing LDL-choles-
terol, thereby increasing coronary heart disease risk. Therefore,
plasma zeaxanthin in human subjects after dietary supplemen-
tation with a natural, cholesterol-free food is of interest. This
was the main focus of this study, in which response to 28-d sup-
plementation with wolfberry was determined in a controlled,
human intervention trial.
Methods and materials
This study had the approval of the Ethics Committee of The Hong
Kong Polytechnic University, and all procedures involving human
subjects complied with the Declaration of Helsinki, as revised in
2000.
This was a single-blinded, placebo-controlled, human interven-
tion trial of 28 d duration and of parallel design. A total of twenty-
seven apparently healthy Chinese adults were recruited with their
informed consent. The age range of the subjects was 18–48 years
(mean 27·6 (SD 9·5)). BMI of volunteers ranged from of 17·9 to
24·7 kg/m2 (mean 20·8 (SD 2·2)). Inclusion criteria included that
subjects did not smoke, were not obese, and had no history of
glaucoma, cataract, age-related macular degeneration or other
retinal diseases. Subjects were excluded if they took regular anti-
oxidant or carotenoid-rich supplements or had a history of serious
or chronic disease. Subjects were allocated, on a non-selective
basis, but stratified for age and BMI, to the control group (n
13; no supplement) or the study group (n 14; 15 g/d commercially
available heat-dried wolfberries (‘Rich Nature’ brand, kindly sup-
plied by Rich Nature Nutraceutical Labs Inc., Lynwood, USA).
Each volunteer in the study group was provided with a 14-d
supply (210 g) of wolfberry, along with instructions on how to
prepare their daily supplement. The method of preparation
adopted in this study was selected to mimic common usage, but
in a standardised manner. In brief, two spoonfuls (a spoon of stan-
dard size was supplied) of the berries were added to one cup
(around 250 ml) of boiling water and left to stand for around
15 min. The softened berries were then mashed with the back of
the spoon, and the berries and water were ingested. Volunteers
were requested to take the berries in the evening, shortly after
their evening meal. This time was chosen, and the berries frag-
mented, because carotenoids are more bioavailable in fragmented
foods and if taken with fat (Hammond et al. 1997; Castenmiller &
West, 1998; Bone et al. 2000). For the control group, a cup of
warm water was taken after dinner each evening for 28 d. After
14 d, members of the study group returned the berry container,
and the remaining 14-d supply (210 g) of berries was provided.
Compliance was checked by regular telephone calls and e-mail
contact, and by checking the contents of the returned container.
Fasting blood was collected, from the antecubital vein, into
commercial heparinised blood collection tubes at baseline (day
1) and after 28 d. Blood samples were kept at 48C and in the
dark until separation of plasma, which was within 3 h of collec-
tion. Plasma was aliquoted and immediately placed at 2708C.
All plasma samples (days 1 and 29 from experimental and control
groups) were run in the same batch to minimise analytical vari-
ation. Plasma lutein concentrations were also measured in these
samples.
Zeaxanthin and lutein were measured simultaneously in
extracted plasma using a reversed phase isocratic HPLC
method. Pure zeaxanthin and lutein were purchased from Indofine
Chemical Company Inc. (Hillsborough, NJ, USA), and purity was
checked using HPLC (only one peak was found on the chromato-
gram of each; results not shown). Absolute ethanol, tetrahydro-
furan and hexane (all Chromasolv for HPLC) were from
Riedel-de Haen (Sigma-Aldrich Laborchemikalien GmbH,
Seelze, Germany), butylated hydroxytoluene (BHT) was from
Sigma (St. Louis, MO, USA), ascorbic acid was from E. Merck
(Darmstadt, Germany) and acetonitrile (HiperSolv for HPLC)
was from BDH Laboratory Supplies (Poole, UK). Milli-Q water
was used (Millipore Corp. Billerica, MA, USA). The chromatog-
raphy system included an Alliance 2695 Separation Module with
temperature-controlled column chamber and autosampler
(Waters, Milford, MA, USA), Waters 2996 Photodiode Array
Detector and Waters Empower Pro PDA software (version
5.00.00.00), a reversed-phase Luna C18 analytical column
(5mm, 250 £ 4·6 mm i.d.; Phenomenex, Torrance, CA, USA)
and a cartridge guard column (Security Guard, C18, cartridge
4 £ 3·0 mm i.d., from Phenomenex). The mobile phase was
0·1 % (w/v) BHT in acetonitrile, which was filtered and degassed
through a Millipore membrane (type GV, pore size 0·22mm,
Millipore Corp.) before use. Detection was at 450 nm. On the
basis of preliminary work, the flow rate was time-programmed
at two speeds, 1·0 ml/min for 0–12 min post-injection, and
2·5 ml/min for 12–60 min. The columns worked under room tem-
perature but the autosampler cooling chamber was at 48C.
Zeaxanthin and lutein are sensitive to light and oxygen. To
minimise degradation, all procedures for preparing calibrators,
controls and test samples were performed in dim light, and evap-
oration of extracts was under nitrogen. In addition, two antioxi-
dants were added (0·1 % w/v ascorbic acid in aqueous phase
and 0·1 % w/v BHT in non-aqueous phase) to minimise oxidative
losses during sample processing and analytical procedures, and
aluminium foil was used to wrap sample containers to protect
from direct illumination of light. Stock standards of pure
zeaxanthin and lutein were prepared in 0·1 % (w/v) BHT in tetra-
hydrofuran. On the day of use, these were diluted in 0·1 % (w/v)
BHT in ethanol and mixed, immediately prior to use, to provide
working calibrators over the expected concentration range.
The extraction procedure was modified from that described by
Aebischer et al. (1999). For calibrators, 200ml of pooled hepari-
nised plasma (in a 1·5 £ 10 cm glass, screw-capped test-tube) was
firstly mixed with 200ml of Milli-Q water containing ascorbic
acid (0·1 % w/v). To this solution, 20ml of one of the calibrators
and 380ml of 0·1 % (w/v) BHT–ethanol were added. The mixture
was vortexed for 30 s., following addition of 800ml of hexane
containing BHT (0·1 % w/v), the tubes (covered with aluminium
foil) were placed on a horizontal mixer (Denley Spiramix 5;
Denley Instruments Ltd, Billinghurst, UK) for 30 min. The sus-
pension was then centrifuged in a Jouan CR4-12 centrifuge
(Jouan Ltd, France) at 2000 rpm, 48C, for 10 min. A 400ml aliquot
of hexane (upper layer) containing the extracted zeaxanthin was
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withdrawn and evaporated to dryness at ,408C under a slow
stream of nitrogen. The residue was then vortexed with 20ml of
tetrahydrofuran (containing 0·1 % w/v BHT), followed by
addition of 80ml of mobile phase. The mixture was again vor-
texed to re-dissolve the residue. These extraction procedures
were performed for all calibrators on the day of use. For extrac-
tion of test plasma or control, 200ml of plasma or control (zeax-
anthin-spiked pooled plasma) were mixed with 200ml of 0·1 %
(w/v) ascorbic acid–water and 400ml of 0·1 % (w/v) BHT–etha-
nol in the first step, with the rest of the extraction as above.
Finally, 25ml of each extracted calibrator, sample or control
was injected into the HPLC system. Peak areas of zeaxanthin
and lutein were recorded from each chromatogram. By plotting
the peak areas against concentrations, calibration curves were
constructed. The concentration of each sample was calculated
by dividing the peak area in the sample by the slope of the appro-
priate calibration curve.
The linear range was determined by direct injections of stan-
dards at various concentrations. Linearity of response was
assessed from the coefficient of correlation (r) of the regression
line. Six replicates of each calibrator at various concentrations
were used to assess within-day precision. The slopes from
assays on 6 d (consecutive) were used to assess between-day pre-
cision. Precision was also assessed using separate extractions and
injections of pooled plasma and pooled plasma spiked with zeax-
anthin and lutein. To determine the limit of detection (LD), the
signal to noise ratio limit was at least 2:1. The LD is the smallest
amount that can be differentiated from zero, and was calculated as
meanþ3SD of ten blank readings. For recovery studies, pooled
plasma was spiked with zeaxanthin and lutein, and native (n 4)
and spiked plasma samples (n 4) were then extracted and assayed.
By comparing results on samples with those obtained with direct
injections of the same (spike) amounts of pure zeaxanthin and
lutein (n 4 each), recoveries were assessed.
Using this method, the peaks for lutein and zeaxanthin were
well resolved, and both eluted within 12 min (Fig. 1). b-Carotene
eluted very slowly, taking more than 2 h at a flow rate of 1·0 ml/
min to appear. As this b-carotene peak may interfere and overlap
with peaks of interest in subsequent samples, sample injection
intervals must be long enough to allow column washout. To
avoid overly long injection intervals, the flow rate was pro-
grammed to increase to 2·5 ml/min once lutein and zeaxanthin
had eluted (i.e. after 12 min). With this setting, b-carotene
eluted at around 55 min, and the auto-injection interval was set
to 60 min, giving an acceptable throughput. Within-day coeffi-
cients of variation (CVs) for zeaxanthin were 4 % at 0·01mmol/
l and 4 % at 0·04mmol/l (n 6): between-day CVs were 7 % at
0·018mmol/l and 6 % at 0·03mmol/l (n 6). Within-day CVs for
lutein were 7 % at 0·35mmol/l and 3 % at 0·87mmol/l (n 6).
Between-day CVs for lutein were 9 % at 0·35mmol/l and 5 % at
0·70mmol/l (n 6). Recovery of 0·009 nmol zeaxanthin was
96·1 % (n 4). Dose–response for zeaxanthin is shown in Fig. 2.
Linearity was maintained at least up to 1·75mmol/l (r 0·9998)
zeaxanthin. The LD was 0·5 pmol; under the assay conditions
used this is equivalent to an LD of 0·0024mmol/l for plasma zeax-
anthin (also for lutein). The sensitivity of the analysis, or mini-
mum detectable difference, was estimated based on the
meanþ3SD of peak areas obtained by six replicate extractions
and injections of pooled plasma, and was 0·0027mmol/l.
Carotenoids are carried in plasma within lipoproteins and are
affected by lipid levels, therefore both total (as mmol/l) and
lipid-standardised (as nmol zeaxanthin (or lutein) per mmol
total cholesterol plus triacylglycerol) concentrations are pre-
sented. Plasma total cholesterol and triacylglycerol were
measured using commercial test kit methods (Biosystems S.A.,
Spain) on a Cobas Fara centrifugal analyser (Roche, Basel, Swit-
zerland).
To explore the dose of zeaxanthin supplied by the berries used
in the supplementation study, a weighed sample of berries was
extracted, zeaxanthin esters were hydrolysed and the total zeax-
anthin content estimated by HPLC. Berries were homogenised
in 0·5 ml of 6 M-NaOH, and 1 ml of absolute ethanol containing
0·1 % (w/v) BHT was added. The mixture was sonicated for
3 min, followed by incubation at 508C for 3 h for hydrolysis of
zeaxanthin esters, after which 0·5 ml of 6 M-HCl was added and
the pH of the mixture adjusted to 7. Two ml of hexane containing
0·1 % (w/v) BHT was added for extraction of carotenoids, with
mixing (on a Denley Spiramix 5) for 30 min, after which the sus-
pension was centrifuged in a Jouan CR4-12 centrifuge (Jouan
Ltd) at 2000 rpm, 48C, for 10 min. One ml of the hexane layer
was removed and evaporated to dryness under a stream of nitro-
gen at 408C. The residue was re-dissolved in 20ml of tetrahydro-
furan containing 0·1 % (w/v) BHT and 80ml of 100 % acetonitrile
containing 0·1 % (w/v) BHT, and 5ml of the redissolved extract
was injected into the HPLC system for determination of zeax-
anthin and lutein. This procedure was performed once only, was
not intended to be a definitive assessment of the zeaxanthin con-
tent of wolfberry, but aimed to furnish an approximation of the
daily dose of zeaxanthin in the berries ingested.
For statistical analysis, Graphpad Prism was used (version 3.0,
San Diego, USA). The pre-versus post- data were analysed using
the Wilcoxon matched pairs test to compare data on days 1 and 29
for each subject. The Mann–Whitney test was used to compare
responses to wolfberry and placebo; P,0·05 was considered
significant.
Results
Demographic information on the control and study groups is sum-
marised in Table 1. There were no significant differences in age,
weight or BMI between the two groups. Day 29 samples were not
available for three subjects in the control group, and for one sub-
ject in the study group; data are presented for ten control subjects
and thirteen supplemented subjects.
The concentration of zeaxanthin (after hydrolysis) in the berries
extracted was estimated at 194mg/g. Based on this, the 15 g sup-
plement provided an additional dietary intake of zeaxanthin of
approximately 3 mg/day. The lutein content of the berries,
which was measured at the same time as zeaxanthin, was much
lower, at 5·8mg/g. Therefore the daily berry intake would have
provided ,0·1 mg/d of additional lutein. After 28-d supplemen-
tation, the lutein concentration of fasting plasma had not changed
significantly. However, there was a significant (P,0·01) and
marked increase in both the total and the lipid-standardised
plasma zeaxanthin concentrations (Table 2). One subject
showed a poor response, with a pre–post difference of
0·007mmol/l in plasma zeaxanthin. This subject had the highest
pre-supplementation fasting plasma zeaxanthin concentration,
but no significant correlation overall was seen between pre-sup-
plementation plasma zeaxanthin concentrations and the magni-
tude of individual responses (r 20·517; P.0·05). The data for
this subject are included in Table 2.
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Discussion
The human diet is estimated to supply 1·3–3 mg/d of lutein and
zeaxanthin combined (Sommerburg et al. 1998). However, as
most xanthophyll-containing foods, such as corn, spinach, broc-
coli, orange and kiwi fruit, contain four to seven times more
lutein than zeaxanthin, dietary zeaxanthin intake is usually low
and fasting plasma levels of zeaxanthin are generally
,0·1mmol/l (Bone et al. 2003; Breithaupt et al. 2004; Hartmann
et al. 2004). To date, lutein has been the xanthophyll of interest in
most AMD-related supplementation studies (Sommerburg et al.
1998; Johnson et al. 2000; Landrum & Bone, 2001; Bone et al.
2003). Data on plasma and macular pigment density changes fol-
lowing zeaxanthin supplementation are scarce, but are of interest
in relation to the more specific accumulation of zeaxanthin in the
central macula of humans (Bone et al. 2000).
The study of Hartmann et al. (2004) reported that fasting
plasma zeaxanthin concentrations increased around 4-fold and
20-fold, from an arithmetic mean of 0·05mmol/l at baseline to a
geometric mean of 0·20 and 0·92mmol/l after 6 weeks of sup-
plementation with, respectively, 1 and 10 mg/d of pure, synthetic,
non-esterified zeaxanthin (n 10 for each dose). Absorption kin-
etics were monitored for 24 h post-ingestion of both doses, and
peak levels were seen at 10–15 h. The 0–24 h area under the
curve (AUC) for the 10 mg dose was almost six times higher
than that of the 1 mg dose after a single dose and after 6 weeks
of daily dosing, but individual responses were highly variable
(Hartmann et al. 2004). Plasma levels reached .90 % of
Table 1. Demographics of study (n 14) and control (n 13) groups
Study group Control group
Mean SEM Mean SEM
Age range (years) 18–44 18–48
Age (years) 28·0 2·68 27·2 2·54
Height (m) 1·59 0·016 1·62 0·025
Weight (kg) 51·39 1·76 57·68 2·92
Fig. 1. Chromatogram of extracted plasma from a single volunteer, pre- (A) and post- (B) supplementation. Peaks of lutein (L) and zeaxanthin (Z) (identified by
comparison with injection of pure lutein and zeaxanthin) are arrowed.
Fig. 2. Representative calibration curve for zeaxanthin: each point is mean of
four readings (separate extractions) with ^2SD error bars shown.
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steady-state concentration after around 17 d of supplementation,
and levels decreased rapidly when the supplementation was
stopped (Hartmann et al. 2004). This rapid decrease in plasma
zeaxanthin after discontinuation of dosing was seen also by
Bone et al. (2003), who reported plateau fasting levels of 0·56
and 0·48mmol/l in each of two subjects who had been sup-
plemented with 30 mg/d of crystalline, unesterified zeaxanthin
for several weeks. This represented a 5–6-fold increase from
baseline. In the study by Breithaupt et al. (2004), twelve subjects
took (separately) two zeaxanthin-based extracts of wolfberry.
Plasma levels after ingestion of both extracts plateaued at about
9 h post-ingestion, and the increase in plasma zeaxanthin averaged
0·02mmol/l after the unesterified zeaxanthin extract, and about
0·06mmol/l after ingestion of the same amount (5 mg) of the
esterified (dipalmitate) extract. The plasma zeaxanthin response
in terms of 0–24 h AUC was significantly higher, but was also
much more variable, following ingestion of the esterified extract,
but the speed of response to both types appeared similar
(Breithaupt et al. 2004). The authors suggested that the greater
variation of response following ingestion of the esterified form
may be due to variation in intestinal lipase activity, and that the
dipalmitate form may be more bioavailable than the more polar,
non-esterified form because of more effective micelle formation.
It is of interest that no increase in plasma levels of zeaxanthin
esters was seen following ingestion of the esterified form of zeax-
anthin (Breithaupt et al. 2004).
In plant foods, zeaxanthin is found mainly in the esterified form
(Lam & But, 1999; Zhou et al. 1999; Krinsky et al. 2003; Weller
& Breithaupt, 2003). Zeaxanthin is found in relatively high concen-
tration in egg yolk (210mg/yolk), but this is mainly in the unester-
ified form. The petals of some flowers, such as marigold, are also
a rich source of zeaxanthin (500mg/100 mg) (Handleman et al.
1999; Olmedilla et al. 2001). Marigold extracts are available as sup-
plements, but flowers are not a common component of the human
diet. Wolfberry is rich in zeaxanthin dipalmitate, but estimates of
berry content vary depending on grade and source of the berries.
Lam & But (1999) reported a total zeaxanthin content of between
1·1 and 4·3 mg/100 g, with an average of 2·4 mg/100 g, in five differ-
ent samples of wolfberry. Leung et al. (2001) stated that values of
30 mg/100 g have been found. Weller & Breithaupt (2003) reported
a much higher content (82 mg/100 g). We performed an exploratory
study of zeaxanthin content of the berries used in this study and,
based on the 19·4 mg/100 mg found, estimate the dose supplied in
the 15 g daily dose of berries to be around 3 mg zeaxanthin.
Spinach and corn are also rich in lutein and zeaxanthin. However,
increased intake of cooked spinach and corn did not lead to an
increase in plasma zeaxanthin concentrations (Bone et al. 2000;
Mozaffarieh et al. 2003). Clearly, the issue of bioavailability of
zeaxanthin from different foods, as well as in different purified
forms, is an important one. It is known that ingestion of fat is
needed to facilitate absorption of carotenoids, and this may help
explain the high bioavailability of zeaxanthin in egg yolk (Handle-
man et al. 1999). However, it is possible that zeaxanthin is less well
absorbed and distributed than lutein (Castenmiller & West, 1998;
Bone et al. 2003). The study of Bone et al. (2003) showed that the
relative change in plasma lutein was twice that of zeaxanthin in
the same subject supplemented with 30 mg/d lutein and, separately,
zeaxanthin, and the plateau supplementation-induced plasma zeax-
anthin level was less than one-third that of lutein (Bone et al. 2003).
However, as pointed out by the authors, the low response to zeax-
anthin may have been due to differences in the formulations used,T
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as the lutein used was esterified and the zeaxanthin was
unesterified (Bone et al. 2003).
Increased intake of some zeaxanthin-rich foods does increase
plasma zeaxanthin concentration. Supplementation with egg
yolk was reported (Handleman et al. 1999) to increase plasma
lutein and zeaxanthin by, respectively, 28 % and 142 %. However,
LDL-cholesterol increased also, by approximately 10 %. This
increase is estimated to increase long-term heart disease risk by
14 % in men with baseline cholesterol concentrations about
5·2 mmol/l, the upper limit of the desirable range; the same
increase in men with higher cholesterol concentrations would
increase risk of heart disease to a greater extent
(Verschuren et al. 1995). Therefore an egg yolk-based dietary
strategy to increase plasma zeaxanthin cannot be recommended,
and an alternative, cholesterol-free, food source is desirable. In
this current study, we demonstrate a mean post-supplementation
level of 0·096mmol/l, a 250 % increase, in fasting plasma zeax-
anthin after 4 weeks of supplementation with whole wolfberries
estimated to supply ,3 mg/d total zeaxanthin, more than is con-
tained in a dozen egg yolks, and no deleterious effects on plasma
lipids were seen (results not shown).
AMD is the leading cause of blindness in the elderly, is more
common in smokers, and is associated with thinning of the macu-
lar pigment (Hyman & Neborsky, 2002; Krinsky et al. 2003).
There are observational data to support the link between increased
intake of xanthophyll-rich foods and lower risk of AMD, but
cause and effect relationships are still tenuous (Krinsky et al.
2003). It is believed that the beneficial effects of increased
intake of lutein and zeaxanthin are mediated by increased macular
pigment. A significant increase in macular pigment in association
with increased plasma lutein has been reported in human subjects
after 4 or more weeks of supplementation with lutein supplements
or lutein-rich food, but not all studies find this (Hammond et al.
1997; Landrum et al. 1997; Sommerburg et al. 1998; Moeller
et al. 2000; Mares-Perlman et al. 2002; Bartlett & Eperjesi,
2003; Bone et al. 2003; Mozaffarieh et al. 2003). This may be
owing to the type of supplement or food used, and to the duration
of the dosing. It has been suggested also that there may be
‘responders’ and ‘non-responders’ to increased xanthophyll
intake, and published data show very variable responses, both
in time and magnitude (Hammond et al. 1997; Leung et al.
2001; Bone et al. 2003; Breithaupt et al. 2004; Hartmann et al.
2004). In the study by Leung et al. (2001), serum zeaxanthin
and lutein concentrations in rhesus monkeys (n 3) were measured
before and after 6 weeks of supplementation with 2·2 mg zeax-
anthin/d in the form of a wolfberry extract. Serum zeaxanthin
concentrations were reported to increase 2·5-fold compared with
basal levels, and the average zeaxanthin content in the maculae
of the treated animals was twice that of control animals. However,
examination of the data (Leung et al. 2001) shows that one of the
three animals fed an extract of wolfberry showed no increase in
plasma zeaxanthin. Intriguingly, though having the lowest pre-
and post-supplementation plasma zeaxanthin levels, this animal
was shown to have the highest macular content of zeaxanthin at
the end of the study. The significance of this finding is not
clear. Furthermore, contrary to humans who accumulate zeax-
anthin in the central area of the macula, the species used in the
study, rhesus monkeys (Macaca mulatto), concentrate lutein cen-
trally (Leung et al. 2001).
In human studies (Hammond et al. 1997; Landrum et al. 1997;
Bone et al. 2003) increased macular pigment density has been
reported with lutein and zeaxanthin supplementation. Interest-
ingly, data from a small (n 2) human study of high-dose zeax-
anthin supplementation (30 mg/d; Bone et al. 2003) showed that
the increase in macular pigment lagged behind that in plasma
zeaxanthin. Plateau plasma levels of zeaxanthin were seen after
about 30 and 10 d of supplementation for the two subjects studied,
but macular pigment did not begin to increase until 1–2 weeks
after these times. However, thereafter the macular pigment
increased in an approximately linear way. In the single subject
who continued with supplementation to 120 d, the macular
pigment density plateaued at about 20 weeks after the
Table 3. Summary of human trials of fasting plasma response to zeaxanthin supplementation
Supplement type, dose
and duration n
Post-supplementation fasting
plasma zeaxanthin in absolute
(mmol/l) and relative terms Comment Reference
Pure, synthetic, unesterified
zeaxanthin; 1 mg/d and
10 mg/d for 42 d
10 Mean 0·20 (SD 0·07)
at 1 mg dose
( £ 4 increase) and
0·92 (SD 0·28) at 10 mg
dose ( £ 20 increase)
Parallel study;
dose–response
seen ( £ 10 dose
gave £ 5 response)
Hartmann et al. (2004)
Crystalline,
unesterified zeaxanthin;
30 mg/d for 60 d (one
subject) and 120 d
(one subject)
2 Individual values: 0·48
( £ 5 increase); 0·56
( £ 6 increase)
Plateau reached for
one subject at ,10 d;
,30 d for the other;
zeaxanthin response
lower than to same
dose of esterified lutein
Bone et al. (2003)
1·5 egg yolks/d supplying
,280mg/d zeaxanthin
(.90 % in unesterified form)
for 32 d (4·5 weeks)
11 Mean 0·105 (SD 0·023) with
corn oil diet ( £ 2 increase);
0·116 (SD 0·027) with beef
tallow diet ( £ 2·5 increase)
Cross-over study;
zeaxanthin in egg
yolk highly bioavailable;
8–11 % increases
seen in plasma LDL
Handleman et al. (1999)
15 mg/d wolfberries
for 28 d; whole berry
supplement estimated
to provide ,3 mg/d
esterified zeaxanthin
27 (test
group, n 14;
control
group, n 13)
Mean 0·096 (SD 0·034)
( £ 2·5 increase)
in test group
Controlled intervention
trial; parallel design;
no significant correlation
seen between fasting
zeaxanthin at entry and
magnitude of response
This study
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supplementation had begun. Interestingly, this was 20 d after sup-
plementation was stopped, and when plasma levels had decreased
to pre-supplementation levels. The speed of both plasma and
macular changes in one of the subjects was faster than the other
(Bone et al. 2003). Similar findings were reported for lutein
(Landrum et al. 1997). This is congruent with the concept that
plasma xanthophyll supply helps determine macular delivery
and enrichment. It is interesting to note also that, while the
plasma concentration decreased rapidly when supplementation
was discontinued, the macular pigment was maintained at its
higher, supplementation-related level for the following 4 months
(Bone et al. 2003). The authors suggested that this could indicate
that continued high-dose supplementation may not be necessary
for maintenance of the macular pigment, and that an initial load-
ing followed by a low maintenance dose may be adequate (Bone
et al. 2003). The recent finding that the esterified form of zeax-
anthin (zeaxanthin dipalmitate) induces a greater plasma response
than the unesterified form (Breithaupt et al. 2004) suggests that
the increases in macular pigment seen after 30 mg/d of unesteri-
fied zeaxanthin (Bone et al. 2003) could be induced by a smaller
dose of esterified zeaxanthin. This remains to be confirmed.
When data from different studies were pooled, significant cor-
relation was seen between the dosage of lutein and the plateau
plasma concentration attained, and between this and the rate of
increase in macular pigment density (Bone et al. 2003). For zeax-
anthin, there is evidence that greater doses induce a greater
plasma response (Hartmann et al. 2004), but individual response
varies widely. At this time it does not appear that the magnitude
of plasma response is determined or limited by the pre-existing
plasma concentration per se. Data in relation to dose of zeax-
anthin and plasma levels attained after a period of supplemen-
tation are summarised in Table 3. Insufficient data exist at this
time to investigate correlation between increases in plasma zeax-
anthin and macular pigment density response, and further work is
needed in this area.
In conclusion, results of this controlled, food-based, sup-
plementation trial show that short-term supplementation with a
modest daily dose (15 mg) of whole wolfberries taken in a similar
way as in normal dietary practice markedly increased zeaxanthin
in fasting plasma of healthy subjects. Therefore, wolfberry offers
an inexpensive, effective and safe whole food dietary strategy to
increase plasma zeaxanthin concentration. The implications for
benefit of wolfberry intake in terms of ocular health are strong.
Longer-term supplementation studies are now needed in regard
to the potential for wolfberry to increase macular pigment density
and help maintain visual acuity in our ageing population through
its effect on plasma zeaxanthin concentration.
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